keyword
MENU ▼
Read by QxMD icon Read
search

vonoprazan

keyword
https://www.readbyqxmd.com/read/27909552/vonoprazan-20-mg-vs-lansoprazole-30-mg-for-endoscopic-submucosal-dissection-induced-gastric-ulcers
#1
Kazuya Takahashi, Yuichi Sato, Junji Kohisa, Jun Watanabe, Hiroki Sato, Kenichi Mizuno, Satoru Hashimoto, Shuji Terai
AIM: To compare the healing effects of vonoprazan and lansoprazole on gastric ulcers induced by endoscopic submucosal dissection (ESD). METHODS: Data were obtained from a total of 26 patients. Fourteen patients were randomized to the vonoprazan group and 12 were randomized to the lansoprazole group. Patients were administered either 20 mg vonoprazan or 30 mg lansoprazole per day after ESD. Endoscopic images just after ESD, on day 8, and on day 28 were used for the evaluation of the shrinking rate of ESD ulcers...
November 16, 2016: World Journal of Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/27891632/randomised-clinical-trial-efficacy-and-safety-of-vonoprazan-vs-lansoprazole-in-patients-with-gastric-or-duodenal-ulcers-results-from-two-phase-3-non-inferiority-randomised-controlled-trials
#2
H Miwa, N Uedo, J Watari, Y Mori, Y Sakurai, Y Takanami, A Nishimura, T Tatsumi, N Sakaki
BACKGROUND: Vonoprazan is a new potassium-competitive acid blocker for treatment of acid-related diseases. AIM: To conduct two randomised-controlled trials, to evaluate the non-inferiority of vonoprazan vs. lansoprazole, a proton pump inhibitor, for treatment of gastric ulcer (GU) or duodenal ulcer (DU). METHODS: Patients aged ≥20 years with ≥1 endoscopically-confirmed GU or DU (≥5 mm white coating) were randomised 1:1 using double-dummy blinding to receive lansoprazole (30 mg) or vonoprazan (20 mg) for 8 (GU study) or 6 (DU study) weeks...
November 27, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27888863/helicobacter-pylori-related-diseases
#3
Javier P Gisbert
This article describes the main conclusions drawn from the presentations on Helicobacter pylori infection in Digestive Diseases Week, 2016. Despite the undeniable widespread reduction in the prevalence of this infection, infection rates continue to be high in developing countries. The prevalence of clarithromycin, metronidazole and quinolone resistance is markedly high in most countries and continues to rise. The management of H. pylori infection in patients with peptic ulcers still leaves much to be desired...
September 2016: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/27867688/usefulness-of-vonoprazan-a-potassium-ion-competitive-acid-blocker-for-primary-eradication-of-helicobacter-pylori
#4
Shinya Yamada, Takumi Kawakami, Yoshikazu Nakatsugawa, Takahiro Suzuki, Hideki Fujii, Naoya Tomatsuri, Hideki Nakamura, Hideki Sato, Yusuke Okuyama, Hiroyuki Kimura, Norimasa Yoshida
AIM: To investigate usefulness of triple therapy with vonoprazan, a potassium ion-competitive acid blocker and antibiotics, for Helicobacter pylori (H. pylori) eradication. METHODS: The H. pylori eradication rate was examined in 2507 patients (2055 undergoing primary eradication and 452 undergoing secondary eradication, excluding patients with subtotal gastrectomy) at the Japanese Red Cross Kyoto Daiichi Hospital from March 2013 to September 2015. For patients treated from March 2013 to February 2015, a proton pump inhibitor (PPI) was used to reduce acid secretion, while vonoprazan was used after March 2015...
November 6, 2016: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27859641/effects-of-vonoprazan-on-intractable-nsaid-induced-ulcers-that-cannot-be-controlled-with-conventional-proton-pump-inhibitors-a-case-report
#5
Kazuhiro Mizukami, Kazunari Murakami
A 53-year-old woman was referred to our hospital for examination of epigastric pain. Medical history included rheumatoid arthritis and fibromyalgia, for which she had been prescribed diclofenac at 75 mg/day and morphine. She had experienced repeated nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers, but pantalgia could not be controlled with anything other than diclofenac, which she was continuing to take orally for ten years. This article is protected by copyright. All rights reserved.
November 17, 2016: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/27806639/analysis-of-the-cost-effectiveness-of-using-vonoprazan-amoxicillin-clarithromycin-triple-therapy-for-first-line-helicobacter-pylori-eradication
#6
Yusaku Kajihara, Tadashi Shimoyama, Ichiro Mizuki
BACKGROUND: Vonoprazan (VPZ)-based triple therapy has been reported to have greater efficacy than a proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori (H. pylori) eradication. However, because VPZ is more expensive than PPIs such as rabeprazole (RPZ), economic evaluation is essential. METHODS: We performed a retrospective study on 209 patients who underwent first-line eradication of H. pylori infection in Fuyoukai Murakami Hospital from 1 March 2015 to 31 March 2016...
November 3, 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27803739/vonoprazan-based-therapy-for-helicobacter-pylori-eradication-experience-and-clinical-evidence
#7
REVIEW
Yuko Akazawa, Daisuke Fukuda, Yutaka Fukuda
Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27689190/a-novel-potassium-competitive-acid-blocker-improves-the-efficacy-of-clarithromycin-containing-7-day-triple-therapy-against-helicobacter-pylori
#8
Hisatsugu Noda, Seiji Noguchi, Takashi Yoshimine, Shigeki Goji, Kazunori Adachi, Yasuhiro Tamura, Shinya Izawa, Masahide Ebi, Sayuri Yamamoto, Naotaka Ogasawara, Yasushi Funaki, Makoto Sasaki, Kunio Kasugai
BACKGROUND AND AIMS: In Japan, 7-day triple therapy for Helicobacter pylori including clarithromycin (CAM) was approved in 2000. However, antibiotic resistance subsequently reduced this rate to an unacceptable level (70%). Vonoprazan, an orally bioavailable potassium-competitive acid blocker (P-CAB), was approved in Japan in 2014. This could improve eradication rates by increasing the intragastric pH, thus increasing bacterial antibiotic susceptibility. This study compared the efficacy of 7-day triple therapies that included CAM and vonoprazan or proton pump inhibitor (PPI)...
September 2016: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/27659671/helicobacter-pylori-eradication-with-proton-pump-inhibitors-or-potassium-competitive-acid-blockers-the-effect-of-clarithromycin-resistance
#9
Hiroshi Matsumoto, Akiko Shiotani, Ryo Katsumata, Minoru Fujita, Rui Nakato, Takahisa Murao, Manabu Ishii, Tomoari Kamada, Ken Haruma, David Y Graham
BACKGROUND: Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) recently approved for Helicobacter pylori eradication therapy in Japan. AIMS: To compare PPI- and P-CAP-containing triple therapy and vonoprazan-based triple therapy. METHODS: Two hundred ninety-five initial subjects received a PPI-containing triple therapy; the next 125 subjects received vonoprazan-containing triple therapy. Two sequential groups received 7-day eradication regimens consisting of amoxicillin 750 mg, clarithromycin 200 mg both twice a day with standard dose PPI or vonoprazan (20 mg) each twice daily...
November 2016: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/27582888/safety-and-efficacy-of-vonoprazan-based-triple-therapy-against-helicobacter-pylori-infection-a-single-center-experience-with-1118-patients
#10
Daisuke Fukuda, Yuko Akazawa, Fuminao Takeshima, Kazuhiko Nakao, Yutaka Fukuda
No abstract text is available yet for this article.
September 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27581248/pharmacokinetic-drug-drug-interactions-between-vonoprazan-and-low-dose-aspirin-or-nonsteroidal-anti-inflammatory-drugs-a-phase-2-open-label-study-in-healthy-japanese-men
#11
Yuuichi Sakurai, Madoka Shiino, Sayako Horii, Hiroyuki Okamoto, Koki Nakamura, Akira Nishimura, Yukikuni Sakata
BACKGROUND: Gastroprotective agents are recommended for patients receiving low-dose aspirin (LDA) or nonsteroidal anti-inflammatory drugs (NSAIDs). Vonoprazan is a potassium-competitive acid blocker recently approved for the prevention of peptic ulcer recurrence in patients receiving LDA or NSAIDs. METHODS: This phase 2, open-label, single-center study in healthy Japanese males evaluated drug-drug interactions between vonoprazan 40 mg and LDA (100 mg) or NSAIDs [loxoprofen sodium (60 mg), diclofenac sodium (25 mg), or meloxicam (10 mg)] and vice versa...
August 31, 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27534444/vonoprazan-versus-conventional-proton-pump-inhibitor-based-triple-therapy-as-first-line-treatment-against-helicobacter-pylori-a-multicenter-retrospective-study-in-clinical-practice
#12
Satoki Shichijo, Yoshihiro Hirata, Ryota Niikura, Yoku Hayakawa, Atsuo Yamada, Satoshi Mochizuki, Keigo Matsuo, Yoshihiro Isomura, Motoko Seto, Nobumi Suzuki, Hirobumi Suzuki, Shinzo Yamamoto, Takafumi Sugimoto, Tomoya Omae, Makoto Okamoto, Hirotsugu Watabe, Goichi Togo, Noriyuki Takano, Keisuke Fukui, Yuri Ito, Kazuhiko Koike
AIM: Vonoprazan is a potassium-competitive acid blocker, a new type of acid-suppressing drug, and has recently become available for peptic ulcers, gastroesophageal reflux disease, and Helicobacter pylori (H. pylori) eradication. Its efficacy for H. pylori eradication therapy isreported in a phase III randomized controlled trial, and in a single center study. However, the evidence for its efficacy and feasibility is still limited. MATERIAL AND METHODS: We performed a multicenter retrospective study of patients who received first-line H...
August 17, 2016: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/27514776/potassium-competitive-acid-blockers-advanced-therapeutic-option-for-acid-related-diseases
#13
Nobuhiro Inatomi, Jun Matsukawa, Yuuichi Sakurai, Kazuyoshi Otake
Acid-related diseases (ARDs), such as peptic ulcers and gastroesophageal reflux disease, represent a major health-care concern. Some major milestones in our understanding of gastric acid secretion and ARD treatment reached during the last 50years include 1) discovery of histamine H2-receptors and development of H2-receptor antagonists, 2) identification of H(+),K(+)-ATPase as the parietal cell proton pump and development of proton pump inhibitors (PPIs), and 3) identification of Helicobacter pylori (H. pylori) as the major cause of peptic ulcers and development of effective eradication regimens...
August 8, 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27492962/vonoprazan-is-superior-to-proton-pump-inhibitors-in-healing-artificial-ulcers-of-the-stomach-post-endoscopic-submucosal-dissection-a-propensity-score-matching-analysis
#14
Daisuke Maruoka, Makoto Arai, Shingo Kasamatsu, Hideaki Ishigami, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Tomoaki Matsumura, Tomoo Nakagawa, Tatsuro Katsuno, Osamu Yokosuka
BACKGROUND AND AIM: Proton pump inhibitors (PPI) are effective at healing artificial ulcers after endoscopic submucosal dissection (ESD) for gastric neoplasms; however, the efficacy of vonoprazan is not completely understood. The aim of the present study was to determine the healing effect of vonoprazan on artificial ulcers post-gastric ESD relative to PPI. METHODS: Thirty-five patients who underwent gastric ESD between April and November 2015 were treated with vonoprazan 20 mg/day for 4 weeks and subsequently underwent endoscopy for evaluation of ulcer size (V group)...
August 4, 2016: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/27465369/lansoprazole-exacerbates-pemetrexed-mediated-hematologic-toxicity-by-competitive-inhibition-of-renal-basolateral-human-organic-anion-transporter-3
#15
Kenji Ikemura, Yugo Hamada, Chinatsu Kaya, Tomoyuki Enokiya, Yuichi Muraki, Hiroki Nakahara, Hajime Fujimoto, Tetsu Kobayashi, Takuya Iwamoto, Masahiro Okuda
Pemetrexed, a multitargeted antifolate, is eliminated by tubular secretion via human organic anion transporter 3 (hOAT3). Although proton pump inhibitors (PPIs) are frequently used in cancer patients, the drug interaction between PPIs and pemetrexed remains to be clarified. In this study, we examined the drug interaction between pemetrexed and PPIs in hOAT3-expressing cultured cells, and retrospectively analyzed the impact of PPIs on the development of hematologic toxicity in 108 patients who received pemetrexed and carboplatin treatment of nonsquamous non-small cell lung cancer for the first time between January 2011 and June 2015...
October 2016: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/27464849/vonoprazan-prevents-bleeding-from-endoscopic-submucosal-dissection-induced-gastric-ulcers
#16
T Kagawa, M Iwamuro, S Ishikawa, M Ishida, S Kuraoka, K Sasaki, I Sakakihara, K Izumikawa, K Yamamoto, S Takahashi, S Tanaka, M Matsuura, T Hasui, M Wato, T Inaba
BACKGROUND: Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs). AIM: To compare the healing status of ESD-induced gastric ulcers and the incidence of post-ESD bleeding between subjects treated with vonoprazan for 5 weeks and those treated with PPIs for 8 weeks. METHODS: Patients in the vonoprazan group (n = 75) were prospectively enrolled, whereas patients in the PPI group (n = 150) were selected for a 2:1 matched historical control cohort according to baseline characteristics including gastric ulcer size immediately following ESD, age, sex and status of Helicobacter pylori infection...
September 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27432383/pharmacokinetics-and-safety-of-triple-therapy-with-vonoprazan-amoxicillin-and-clarithromycin-or-metronidazole-a-phase-1-open-label-randomized-crossover-study
#17
Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Akira Nishimura, Koki Nakamura, Setsuo Hasegawa
INTRODUCTION: Vonoprazan (TAK-438) is a novel potassium-competitive acid blocker that inhibits gastric H(+), K(+)-ATPase. The objectives of this study were to evaluate the influence of triple therapy with vonoprazan-amoxicillin-clarithromycin or vonoprazan-amoxicillin-metronidazole on the pharmacokinetics of each component of the triple therapies (primary) and to evaluate the safety and tolerability of vonoprazan-based triple therapies (secondary) in healthy adults. METHODS: In this single-center, phase 1, open-label, randomized, four-way crossover study, Helicobacter pylori-negative, healthy Japanese male subjects were randomly assigned to 1 of 4 treatment sequences in two cohorts (12 subjects per cohort)...
September 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27428571/vonoprazan-for-treatment-of-gastroesophageal-reflux-pharmacodynamic-and-pharmacokinetic-considerations
#18
Edoardo Savarino, Irene Martinucci, Manuele Furnari, Chiara Romana, Gaia Pellegatta, Alessandro Moscatelli, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Nicola de Bortoli, Corrado Blandizzi
INTRODUCTION: About 30-40% of GERD patients report an inadequate response to proton pump inhibitors (PPIs) due to their suboptimal pharmacological profiles. Recently, a new synthesized P-CABs, vonoprazan, showed higher suppression of gastric acid secretion as compared to lansoprazole. AREAS COVERED: This review provides an update on the pharmacokinetic properties of vonoprazan and their correlates with pharmacodynamics; preliminary data on the therapeutic efficacy of vonoprazan as compared to lansoprazole in GERD patients Expert opinion: At variance from all available PPIs, vonoprazan acts directly on H+,K+-ATPase irrespectively of its activity, providing a fast onset of action without requiring acid activation and specific administration timing...
August 8, 2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/27414183/in-vitro-metabolism-of-tak-438-vonoprazan-fumarate-a-novel-potassium-competitive-acid-blocker
#19
Hitomi Yamasaki, Naohiro Kawaguchi, Masami Nonaka, Junzo Takahashi, Akio Morohashi, Hideki Hirabayashi, Toshiya Moriwaki, Satoru Asahi
1. TAK-438, vonoprazan fumarate, is a novel orally active potassium-competitive acid blocker, developed as an antisecretory drug. In this study, we investigated the in vitro metabolism of (14)C-labeled TAK-438. In human hepatocytes, M-I, M-II, M-III and M-IV-Sul were mainly formed, and these were also detected in clinical studies. N-demethylated TAK-438 was also formed as an in vitro specific metabolite. Furthermore, CYP3A4 mainly contributed to the metabolism of TAK-438 to M-I, M-III, and N-demethylated TAK-438, and CYP2B6, CYP2C19 and CYP2D6 partly catalyzed the metabolism of TAK-438...
July 14, 2016: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/27316584/comparison-of-vonoprazan-and-proton-pump-inhibitors-for-eradication-of-helicobacter-pylori
#20
Satoshi Shinozaki, Hiroaki Nomoto, Yoshie Kondo, Hirotsugu Sakamoto, Yoshikazu Hayashi, Hironori Yamamoto, Alan Kawarai Lefor, Hiroyuki Osawa
Alternative eradication therapies for Helicobacter pylori infection are needed because of an increasing failure rate over the past decade. The aim of this study was to determine if vonoprazan, a new potassium-competitive acid blocker, showed superiority to existing proton pump inhibitors for primary eradication of H. pylori in routine clinical practice. Data for 573 patients who underwent primary H. pylori eradication therapy were retrospectively reviewed. Regimens included clarithromycin 200 mg, amoxicillin 750 mg, and an acid-suppressing drug [lansoprazole 30 mg (LAC), rabeprazole 10 mg (RAC), esomeprazole 20 mg (EAC), or vonoprazan 20 mg (VAC)] twice daily for 1 week...
May 2016: Kaohsiung Journal of Medical Sciences
keyword
keyword
99659
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"